BP
MGX icon

BBR Partners’s Metagenomi Therapeutics MGX Stock Holding History

BBR Partners’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71.6K Hold
53,403
– – ﹤0.01% 248
2025
Q4 		$86.5K Hold
53,403
– – ﹤0.01% 260
2025
Q3 		$127K Hold
53,403
– – 0.01% 260
2025
Q2 		$79K Hold
53,403
– – ﹤0.01% 230
2025
Q1 		$72.6K Hold
53,403
– – 0.01% 236
2024
Q4 		$193K Buy
+53,403
New +$129K 0.01% 230

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBR Partners's MGX Position: Q1 2026 in Review

BBR Partners held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 53,403 shares worth $71.6K. The position accounts for ﹤0.01% of the portfolio, ranked #248.

BBR Partners first reported a position in MGX in Q4 2024 and has held it in 6 quarters since. The position peaked at $193K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • BBR Partners held 53,403 shares of Metagenomi Therapeutics worth $71.6K as of Q1 2026.
  • BBR Partners left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of BBR Partners's portfolio in Q1 2026, its #248 holding.
  • BBR Partners first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BBR Partners's Metagenomi Therapeutics position peaked at $193K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on BBR Partners's 13F filing for Q1 2026, filed 12 May 2026.